J H Park1, S F Jonas2, G Bataillon3, C Criscitiello4, R Salgado5, S Loi6, G Viale7, H J Lee8, M V Dieci9, S-B Kim10, A Vincent-Salomon11, G Curigliano12, F André13, S Michiels14. 1. Department of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul; Department of Hemato-Oncology, Konkuk Medical Center, University of Konkuk College of Medicine, Seoul, Korea. 2. Department of Biostatistics and Epidemiology, Gustave Roussy; INSERM, Unit 1018, University Paris-Sud, University Paris-Saclay, Villejuif. 3. Department of Pathology, Institut Curie, Université Paris Sciences Lettres, Paris, France. 4. IEO, European Institute of Oncology, IRCCS, Milan, Italy. 5. GZA, Antwerp, Belgium; Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 6. Division of Clinical Medicine and Research, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. 7. Department of Pathology, European Institute of Oncology, IRCCS, Milano, Italy. 8. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 9. Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Veneto Institute of Oncology IOV - IRCCS, Padova, Italy. 10. Department of Medical Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul. 11. Department of Pathology, Institut Curie, Université Paris Sciences Lettres, Paris, France; Inserm Unit 934, Paris, France. 12. IEO, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hemato-Oncology, University of Milano, Milano, Italy. 13. Department of Oncology, Gustave Roussy; INSERM, Unit 981, University Paris-Sud, University Paris-Saclay, Villejuif, France. 14. Department of Biostatistics and Epidemiology, Gustave Roussy; INSERM, Unit 1018, University Paris-Sud, University Paris-Saclay, Villejuif. Electronic address: stefan.michiels@gustaveroussy.fr.
Abstract
BACKGROUND: Although stromal tumor-infiltrating lymphocytes (sTILs) have been considered an important prognostic factor in early-stage triple-negative breast cancer (TNBC), there have been limited data on their prognostic value in the absence of adjuvant chemotherapy. PATIENTS AND METHODS: A pooled analysis was carried out using four cohorts of TNBC patients not treated with chemotherapy. sTILs were evaluated in the most representative tumoral block of surgical specimens. Cox proportional hazards regression models were used for invasive disease-free survival (iDFS), distant disease-free survival (D-DFS), and overall survival (OS), fitting sTILs as a continuous variable adjusted for clinicopathologic factors. RESULTS: We analyzed individual data of 476 patients from 4 centers diagnosed between 1989 and 2015. Their median age was 64 years. The median tumor size was 1.6 cm and 83% were node-negative. The median level of sTILs was 10% (Q1-Q3, 4%-30%). Higher grade was associated with higher sTILs (P < 10-3). During follow-up, 107 deaths, and 173 and 118 events for iDFS and D-DFS were observed, respectively. In the multivariable analysis, sTILs obtained an independent prognostic value for all end points (likelihood ratio χ2 = 7.14 for iDFS; P < 10-2; χ2 = 9.63 for D-DFS, P < 10-2; χ2 = 5.96 for OS, P = 0.015). Each 10% increment in sTILs corresponded to a hazard ratio of 0.90 [95% confidence interval (CI) 0.82 - 0.97] for iDFS, 0.86 (95% CI 0.77 - 0.95) for D-DFS, and 0.88 (95% CI 0.79 - 0.98) for OS, respectively. In patients with pathological stage I tumors with sTILs ≥30% (n = 74), 5-year iDFS was 91% (95% CI 84% to 96%), D-DFS was 97% (95% CI 93% to 100%), and OS was 98% (95% CI 95% to 100%). CONCLUSION: sTILs add important prognostic information in systemically untreated early-stage TNBC patients. Notably, sTILs can identify a subset of stage I TNBC patients with an excellent prognosis without adjuvant chemotherapy.
BACKGROUND: Although stromal tumor-infiltrating lymphocytes (sTILs) have been considered an important prognostic factor in early-stage triple-negative breast cancer (TNBC), there have been limited data on their prognostic value in the absence of adjuvant chemotherapy. PATIENTS AND METHODS: A pooled analysis was carried out using four cohorts of TNBC patients not treated with chemotherapy. sTILs were evaluated in the most representative tumoral block of surgical specimens. Cox proportional hazards regression models were used for invasive disease-free survival (iDFS), distant disease-free survival (D-DFS), and overall survival (OS), fitting sTILs as a continuous variable adjusted for clinicopathologic factors. RESULTS: We analyzed individual data of 476 patients from 4 centers diagnosed between 1989 and 2015. Their median age was 64 years. The median tumor size was 1.6 cm and 83% were node-negative. The median level of sTILs was 10% (Q1-Q3, 4%-30%). Higher grade was associated with higher sTILs (P < 10-3). During follow-up, 107 deaths, and 173 and 118 events for iDFS and D-DFS were observed, respectively. In the multivariable analysis, sTILs obtained an independent prognostic value for all end points (likelihood ratio χ2 = 7.14 for iDFS; P < 10-2; χ2 = 9.63 for D-DFS, P < 10-2; χ2 = 5.96 for OS, P = 0.015). Each 10% increment in sTILs corresponded to a hazard ratio of 0.90 [95% confidence interval (CI) 0.82 - 0.97] for iDFS, 0.86 (95% CI 0.77 - 0.95) for D-DFS, and 0.88 (95% CI 0.79 - 0.98) for OS, respectively. In patients with pathological stage I tumors with sTILs ≥30% (n = 74), 5-year iDFS was 91% (95% CI 84% to 96%), D-DFS was 97% (95% CI 93% to 100%), and OS was 98% (95% CI 95% to 100%). CONCLUSION:sTILs add important prognostic information in systemically untreated early-stage TNBC patients. Notably, sTILs can identify a subset of stage I TNBC patients with an excellent prognosis without adjuvant chemotherapy.
Authors: Zuzana Kos; Elvire Roblin; Rim S Kim; Stefan Michiels; Brandon D Gallas; Weijie Chen; Koen K van de Vijver; Shom Goel; Sylvia Adams; Sandra Demaria; Giuseppe Viale; Torsten O Nielsen; Sunil S Badve; W Fraser Symmans; Christos Sotiriou; David L Rimm; Stephen Hewitt; Carsten Denkert; Sibylle Loibl; Stephen J Luen; John M S Bartlett; Peter Savas; Giancarlo Pruneri; Deborah A Dillon; Maggie Chon U Cheang; Andrew Tutt; Jacqueline A Hall; Marleen Kok; Hugo M Horlings; Anant Madabhushi; Jeroen van der Laak; Francesco Ciompi; Anne-Vibeke Laenkholm; Enrique Bellolio; Tina Gruosso; Stephen B Fox; Juan Carlos Araya; Giuseppe Floris; Jan Hudeček; Leonie Voorwerk; Andrew H Beck; Jen Kerner; Denis Larsimont; Sabine Declercq; Gert Van den Eynden; Lajos Pusztai; Anna Ehinger; Wentao Yang; Khalid AbdulJabbar; Yinyin Yuan; Rajendra Singh; Crispin Hiley; Maise Al Bakir; Alexander J Lazar; Stephen Naber; Stephan Wienert; Miluska Castillo; Giuseppe Curigliano; Maria-Vittoria Dieci; Fabrice André; Charles Swanton; Jorge Reis-Filho; Joseph Sparano; Eva Balslev; I-Chun Chen; Elisabeth Ida Specht Stovgaard; Katherine Pogue-Geile; Kim R M Blenman; Frédérique Penault-Llorca; Stuart Schnitt; Sunil R Lakhani; Anne Vincent-Salomon; Federico Rojo; Jeremy P Braybrooke; Matthew G Hanna; M Teresa Soler-Monsó; Daniel Bethmann; Carlos A Castaneda; Karen Willard-Gallo; Ashish Sharma; Huang-Chun Lien; Susan Fineberg; Jeppe Thagaard; Laura Comerma; Paula Gonzalez-Ericsson; Edi Brogi; Sherene Loi; Joel Saltz; Frederick Klaushen; Lee Cooper; Mohamed Amgad; David A Moore; Roberto Salgado Journal: NPJ Breast Cancer Date: 2020-05-12
Authors: Ann Byrne; Peter Savas; Sneha Sant; Ran Li; Balaji Virassamy; Stephen J Luen; Paul A Beavis; Laura K Mackay; Paul J Neeson; Sherene Loi Journal: Nat Rev Clin Oncol Date: 2020-02-28 Impact factor: 66.675
Authors: Balazs Acs; David L Rimm; Yalai Bai; Kimberly Cole; Sandra Martinez-Morilla; Fahad Shabbir Ahmed; Jon Zugazagoitia; Johan Staaf; Ana Bosch; Anna Ehinger; Emma Nimeus; Johan Hartman Journal: Clin Cancer Res Date: 2021-06-04 Impact factor: 12.531
Authors: Monika Graeser; Friedrich Feuerhake; Oleg Gluz; Valery Volk; Michael Hauptmann; Katarzyna Jozwiak; Matthias Christgen; Sherko Kuemmel; Eva-Maria Grischke; Helmut Forstbauer; Michael Braun; Mathias Warm; John Hackmann; Christoph Uleer; Bahriye Aktas; Claudia Schumacher; Cornelia Kolberg-Liedtke; Ronald Kates; Rachel Wuerstlein; Ulrike Nitz; Hans Heinrich Kreipe; Nadia Harbeck Journal: J Immunother Cancer Date: 2021-05 Impact factor: 13.751
Authors: Giacomo Montagna; Hersh V Gupta; Margaret Hannum; Kay See Tan; Jasme Lee; Joseph R Scarpa; George Plitas; Takeshi Irie; Patrick J McCormick; Gregory W Fischer; Monica Morrow; Joshua S Mincer Journal: Br J Anaesth Date: 2020-11-19 Impact factor: 9.166
Authors: Mercedes Herrera Juarez; Pablo Tolosa Ortega; Ana Sanchez de Torre; Eva Ciruelos Gil Journal: Breast Care (Basel) Date: 2020-06-05 Impact factor: 2.860